SCHEMBL4676970

SCHEMBL4676970

O=C(C=C(O)c1nc[nH]n1)c1coc(-c2ccccc2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.36
ALDH1A1 P00352 6/20 0.36
MEN1 O00255 4/20 0.36
NPC1 O15118 4/20 0.36
HPGD P15428 4/20 0.36
KMT2A Q03164 4/20 0.36
LMNA P02545 4/20 0.36
MAPT P10636 3/20 0.36
RAB9A P51151 3/20 0.36
PKM P14618 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NFE2L2 Q16236 1/20 0.36
POLB P06746 2/20 0.32
HSP90AA1 P07900 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
IKBKE Q14164 1/20 0.31
TBK1 Q9UHD2 1/20 0.31
KDM4E B2RXH2 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672014 0.90 NR4A2 (0.37) NR4A2ALDH1A1MEN1NPC1KMT2A
SCHEMBL4671438 0.89 NR4A1 (0.40) NR4A2HSP90AA1
SCHEMBL4676370 0.85 MEN1 (0.34) ALDH1A1MEN1NPC1HPGDKMT2A
SCHEMBL4671834 0.82 NFE2L2 (0.33) ALDH1A1MEN1NPC1KMT2ALMNA
SCHEMBL4672571 0.81 ALDH1A1 (0.51) ALDH1A1MEN1NPC1HPGDKMT2A
SCHEMBL4672199 0.81 IDH1 (0.40) KMT2ANFE2L2
SCHEMBL4675492 0.81 CHRNA4 (0.41)
SCHEMBL4672006 0.80 HTT (0.36) ALDH1A1MEN1NPC1KMT2ALMNA
SCHEMBL4673558 0.80 KMT2A (0.34) ALDH1A1MEN1NPC1HPGDKMT2A
SCHEMBL4675307 0.80 HPGD (0.46) ALDH1A1MEN1NPC1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 NR4A2 454/4885ALDH1A1 980/4885MEN1 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.